HeartSciences Inc., an AI-powered medical technology company, announced its financial results for the third quarter of fiscal 2025, which ended on January 31, 2025. The company reported no revenues for Q3 FY2025. As of January 31, 2025, HeartSciences held approximately $2.6 million in cash and cash equivalents, with shareholders' equity at around $1.8 million. The company highlighted significant advancements in its business operations, particularly in the AI-enhanced ECG field. HeartSciences is making substantial progress towards FDA submissions for its products, aiming to modernize ECG technology and improve the early detection of heart disease. Additionally, the Centers for Medicare & Medicaid Services $(CMS)$ have established reimbursement for AI-ECG at a rate higher than that of conventional ECG, underscoring the clinical value and commercial potential of the technology.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.